• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Blood levels of soluble ICAM-1 in patients with multiple sclerosis].

作者信息

García-Tortosa C, Amrani Y, Casado A, Muñoz F J, Vázquez J

机构信息

Sección de Neurología, Hospital Torrecárdenas, Almería, España.

出版信息

Rev Neurol. 1998 Jun;26(154):926-9.

PMID:9658462
Abstract

INTRODUCTION

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. The Intercellular Adhesion Molecule plays a fundamental part in the migration of T cells to the inflammed tissues. It is known that there is an increase in the expression of endothelial cells and other cells found in lesions of the central nervous system of MS patients. ICAM-I may be detected in its soluble form in serum and it is of interest to understand its behaviour in this liquid since it is easily accessible.

MATERIAL AND METHODS

We studied the concentration of soluble ICAM-I in the serum of patients with MS: one group which had clinical attacks were studied whilst in remission; another had the chronic progressive clinical form and a third group had optic neuritis as the probable initial sign of the disorder. Within the different clinical forms, some patients received treatment with beta-interferon or azathioprine and others did not.

RESULTS AND CONCLUSIONS

We found a significant increase in the levels of soluble ICAM-I in patients with inactive, untreated MS as compared with normal persons, with no difference found between the different clinical types.

摘要

相似文献

1
[Blood levels of soluble ICAM-1 in patients with multiple sclerosis].
Rev Neurol. 1998 Jun;26(154):926-9.
2
Effect of cladribine treatment on beta-2 microglobulin and soluble intercellular adhesion molecule 1 (ICAM-1) in patients with multiple sclerosis.
Folia Morphol (Warsz). 2001 Aug;60(3):225-8.
3
Multiple sclerosis and optic neuritis: CCR5 and CXCR3 expressing T cells are augmented in blood and cerebrospinal fluid.多发性硬化症与视神经炎:血液和脑脊液中表达CCR5和CXCR3的T细胞增多。
J Neurol. 2002 Jun;249(6):723-9. doi: 10.1007/s00415-002-0699-z.
4
[The level of soluble forms of interleukin-2 receptor and adhesive molecules ICAM-1 and VCAM-1 in platelets of multiple sclerosis patients].[多发性硬化症患者血小板中白细胞介素-2受体及黏附分子ICAM-1和VCAM-1的可溶性形式水平]
Pol Merkur Lekarski. 1999 Jan;6(31):23-6.
5
CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.接受和未接受干扰素β-1b治疗的复发缓解型多发性硬化症患者中的CD45RA+ ICAM-3+淋巴细胞
Acta Neurol Scand. 2004 Dec;110(6):377-85. doi: 10.1111/j.1600-0404.2004.00346.x.
6
Effects of rIFN-beta-1b on serum circulating ICAM-1 in relapsing remitting multiple sclerosis and on the membrane-bound ICAM-1 expression on brain microvascular endothelial cells.重组人干扰素β-1b对复发缓解型多发性硬化症患者血清循环细胞间黏附分子-1及脑微血管内皮细胞膜结合细胞间黏附分子-1表达的影响
J Neurovirol. 2000 May;6 Suppl 2:S47-51.
7
Serum levels of soluble intercellular adhesion molecule-1 (s-ICAM-1) and soluble endothelial leukocyte adhesion molecule-1(s-ELAM-1) in amyotrophic lateral sclerosis.肌萎缩侧索硬化症患者血清中可溶性细胞间黏附分子-1(s-ICAM-1)和可溶性内皮白细胞黏附分子-1(s-ELAM-1)的水平
Amyotroph Lateral Scler Other Motor Neuron Disord. 2005 Jun;6(2):118-21. doi: 10.1080/14660820410021311.
8
Multiple sclerosis. Part 2: ophthalmic issues in MS therapy.多发性硬化症。第2部分:多发性硬化症治疗中的眼科问题。
Curr Opin Ophthalmol. 2009 Nov;20(6):476-81. doi: 10.1097/ICU.0b013e3283319155.
9
Multiple sclerosis: rationale for early treatment.
Neurol Sci. 2003 Dec;24 Suppl 5:S298-300. doi: 10.1007/s10072-003-0179-y.
10
Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.接受β-1b干扰素治疗的多发性硬化症患者体内的细胞因子和黏附分子
Cytokine. 2005 Jan 7;29(1):24-30. doi: 10.1016/j.cyto.2004.09.005.